Incidentaloma medical therapy

Revision as of 23:31, 29 August 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Incidentaloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Incidentaloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Incidentaloma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Incidentaloma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Incidentaloma medical therapy

CDC on Incidentaloma medical therapy

Incidentaloma medical therapy in the news

Blogs on Incidentaloma medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Incidentaloma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

The mainstay of treatment for [disease name] is [therapy].

Medical Therapy

Perioperative management of patients with SCS

  • Patients with Cushing’s syndrome or SCS have adequate circulating glucocorticoids and therefore do not require glucocorticoid therapy during surgery.
  • Such patients can safely undergo surgical resection of their tumor, have their cortisol levels measured in the morning of postoperative d 1
  • be started on hydrocortisone 30 mg in the morning and 10 mg in the early afternoon until the result of the cortisol level becomes available (73).
  • This would provide an early and accurate evaluation of surgical success in patients with underlying Cushing’s syndrome or SCS.
  • Another approach would be to cover all patients with glucocorticoids perioperatively and evaluate their HPA axis at a later date (71, 74).

Aldosteronoma

Preoperative management

  • The majority of patients with primary aldosteronism need to proceed with bilateral adrenal venous sampling to confirm the presence of a unilateral source for hyperaldosteronism.
  • Some experts recommend adrenal vein sampling in all patients with primary aldosteronism older than 40 yr due to the increased prevalence of adrenal incidentaloma in such a population (118).
  • Adrenalectomy in patients with a documented unilateral source of primary aldosteronism is more cost effective compared with lifelong medical therapy.
  • Medical therapy with mineralocorticoid receptor antagonists should be reserved for those who are unable or unwilling to undergo surgery (44).
  • Laparoscopic adrenalectomy compared to an open procedure is associated with a shorter hospital stay, fewer complications, and faster recovery.
  • Resection of the adrenal tumor in a patient with APA will result in resolution of hypokalemia and improvement in hypertension in almost all patients.

Postoperative management

  • Potassium supplementation and mineralocorticoid receptor antagonists should be stopped on postoperative day1
  • Close monitoring of serum potassium.
  • A temporary state of hypoaldosteronism may also develop in some patients with primary aldosteronism postoperatively.
  • In the majority of cases, this condition can be managed by increasing salt intake.

References

Template:WH Template:WS